
http://www.youtube.com/watch?v=SfkcmYR6AXs
Sulfasalazine, a drug commonly prescribed to reduce diarrhea in patients with inflammatory bowel disease, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area. The Mayo Clinic-led study also found that the medication may be associated with a higher risk of diarrhea than a placebo when used during radiation therapy to the pelvis. Robert Miller, M.D., a radiation oncologist and the study's lead author, says, “Patients receiving radiation therapy in the pelvic region can experience diarrhea which is a negative side effect of the therapy.”
The results are being presented at the American Society of Radiation Oncology’s (ASTRO’s) Meeting in Atlanta.
Read news release.
Journalists: Sound bites with Dr. Miller are available in the downloads.
National Influenza Vaccination Week will be observed Dec. 4–8, which makes this a good time to learn more about the flu and why it's especially important ...
When David Elder’s back started to hurt in the fall of 2022, he thought his recurrent spasms had returned. But when medication didn’t help like ...
When Joanina Gicobi began her Ph.D. degree five years ago at Mayo Clinic Graduate School of Biomedical Sciences, she was interested in thinking creatively about ways ...